Used in targeted cancer therapy, particularly in tumors driven by fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptors (VEGFR). It functions as a tyrosine kinase inhibitor, blocking signaling pathways that promote tumor growth and angiogenesis. Investigated in clinical trials for solid tumors, including breast cancer and endometrial cancer, especially in cases with FGFR pathway alterations. Its selectivity makes it a candidate for precision oncology approaches where specific genetic mutations are present.